HORIZON试验三年结果:Schlemm管微支架用于原发性开角型青光眼合并白内障的降压效果
HORIZON多中心随机对照试验纳入556眼白内障合并原发性开角型青光眼患者,比较白内障手术联合Hydrus微支架植入与单纯白内障手术。3年结果显示联合组降眼压药物使用更少、无药比例更高,且需进一步抗青光眼手术的累积概率更低,安全性良好。
要点
- 联合组3年无药比例73%,显著高于单纯手术组48%。
- 联合组眼压≤18 mmHg且无药比例56.2%,高于单纯手术组34.6%。
- 联合组需进一步切开性青光眼手术的累积概率0.6%,低于单纯手术组3.9%。
核心结论
- 白内障手术联合微支架植入治疗轻中度原发性开角型青光眼安全,3年时降眼压更有效且用药更少。
- 联合组较单纯白内障手术更少需要进一步切开性青光眼滤过手术。
研究设计与样本
- 多中心随机临床试验,556眼(556例)合并白内障和原发性开角型青光眼、使用≥1种降眼压药、洗脱后日间眼压22–34 mmHg且无既往切开性青光眼手术史的患者。
主要发现
- 3年时微支架组眼压16.7±3.1 mmHg,单纯手术组17.0±3.4 mmHg(P=0.85)。
- 微支架组降眼压药物数0.4±0.8,单纯手术组0.8±1.0(P<0.001)。
- 微支架组73%无药,单纯手术组48%(P<0.001)。
- 微支架组眼压≤18 mmHg且无药比例56.2%,单纯手术组34.6%(P<0.001),且眼压降幅≥20%、30%、40%的比例更高。
- 微支架组需切开性青光眼手术的累积概率0.6%,单纯手术组3.9%(HR=0.156,95%CI 0.031–0.773,P=0.020)。
关键数值与推荐
- 3年眼压≤18 mmHg且无降眼压药比例:微支架组56.2% vs 单纯手术组34.6%(P<0.001)。
- 3年无降眼压药比例:微支架组73% vs 单纯手术组48%(P<0.001)。
- 需切开性青光眼手术累积概率:微支架组0.6% vs 单纯手术组3.9%(HR=0.156,95%CI 0.031–0.773,P=0.020)。
临床怎么用
- 对轻中度原发性开角型青光眼合并白内障患者,可考虑白内障手术联合Hydrus微支架植入以减少降眼压药物负担。
- 联合手术可降低后续需切开性青光眼滤过手术的风险,且未增加角膜内皮细胞丢失或严重不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report 3-year outcomes of the HORIZON study comparing cataract surgery (CS) with Hydrus Microstent (Ivantis, Inc) implantation versus CS alone. DESIGN: Multicenter randomized clinical trial. PARTICIPANTS: Five hundred fifty-six eyes from 556 patients with cataract and primary open-angle glaucoma (POAG) treated with 1 or more glaucoma medication, washed out diurnal intraocular pressure (IOP) of 22 to 34 mmHg, and no prior incisional glaucoma surgery. METHODS: After phacoemulsification, eyes were randomized 2:1 to receive a Hydrus Microstent or no stent. Follow-up included comprehensive eye examinations through 3 years. MAIN OUTCOME MEASURES: Outcome measures included IOP, medical therapy, reoperation rates, visual acuity, adverse events, and changes in corneal endothelial cell counts. RESULTS: Three hundred sixty-nine eyes were randomized to microstent treatment and 187 to CS only. Preoperative IOP, medication use, washed-out diurnal IOP, and glaucoma severity did not differ between the two treatment groups. At 3 years, IOP was 16.7 ± 3.1 mmHg in the microstent group and 17.0 ± 3.4 mmHg in the CS group (P = 0.85). The number of glaucoma medications was 0.4 ± 0.8 in the microstent group and 0.8 ± 1.0 in the CS group (P < 0.001), and 73% of microstent group eyes were medication free compared with 48% in the CS group (P < 0.001). The microstent group included a higher proportion of eyes with IOP of 18 mmHg or less without medications compared with the CS group (56.2% vs. 34.6%; P < 0.001), as well as IOP reduction of at least 20%, 30%, or 40% compared with CS alone. The cumulative probability of incisional glaucoma surgery was lower in the microstent group (0.6% vs. 3.9%; hazard ratio, 0.156; 95% confidence interval, 0.031-0.773; P = 0.020). No difference was found in postoperative corneal endothelial cell loss between groups. No procedure- or device-related serious adverse events resulting in vision loss occurred in either group. CONCLUSIONS: Combined CS and microstent placement for mild to moderate POAG is safe, more effective in lowering IOP with fewer medications, and less likely to result in further incisional glaucoma filtration surgery than CS alone at 3 years.
引用
- Ahmed IIK, Rhee DJ, Jones J, et al. Three-Year Findings of the HORIZON Trial: A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract. Ophthalmology. 2020. PMID: 33166551. doi:10.1016/j.ophtha.2020.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。